Figure 1.

SC-β cells encapsulated with TMTD alginate sustain normoglycemia in STZ-treated immune competent C57BL/6J mice. (a) SC-β cells were generated using the differentiation protocol described⁴. FACS analysis shows surface markers on cells at indicated differentiation stages. Data is representative of 10 separate differentiations from the HUES8 stem cell line. (Editor: Stage 1–3 is previously described⁴ and not relevant to this manuscript) (b) Brightfield images of encapsulated SC-β cells.. Scale bar = 400 µm, N = 15. (c–e) SC-β cells encapsulated as shown in (b) were transplanted into the intraperitoneal space of STZ-treated C57BL/6 mice, and blood glucose concentrations were measured at indicated times. (c) 500 µm SLG20 alginate microcapsules; (d) 1.5 mm SLG20 alginate microspheres; (e) 1.5 mm TMTD alginate spheres. Three different doses of cell clusters (100, 250, and 1000 cluster per mouse) were implanted under each encapsulation condition. The red dashed line indicates the blood glucose cutoff for normoglycemia in mice. For reference 250 clusters equates to approximately 1 million cells. Error bars, mean ± s.e.m. Quantitative data shown is the average of N = 5 mice per treatment. All experiments were repeated three times for a total of N = 15 mice per treatment.